Micelle-like nanoassemblies based on polymer-drug conjugates as an emerging platform for drug delivery

Expert Opinion on Drug Delivery

Volumn 9, Issue 7, 2012, Pages 805-822

  Liu, Zhihong ^a   Wang, Yutao ^a   Zhang, Na ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

amphiphilic polymer drug conjugates; drug delivery; micelle like nanoassemblies; micelles; targeting mechanisms

Indexed keywords

ALBUMIN; CARBOXYL GROUP; CERTOLIZUMAB PEGOL; COUMARIN; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; FOLATE BINDING PROTEIN; HEPARIN; HERMES ANTIGEN; HYALURONIC ACID; HYDROXYL GROUP; MACROGOL; MICELLE LIKE NANOASSEMBLY; NANOMATERIAL; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGADEMASE; PEGVISOMANT; POLOXAMER; POLYCAPROLACTONE; POLYGLUTAMIC ACID; POLYLACTIDE; POLYMER; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; ZINOSTATIN;

ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ATOM TRANSFER RADICAL POLYMERIZATION; ATOMIC FORCE MICROSCOPY; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER INHIBITION; CELL INTERACTION; CHEMICAL STRUCTURE; CRITICAL MICELLE CONCENTRATION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; ENDOCYTOSIS; HEMOLYSIS; HUMAN; INFRARED SPECTROSCOPY; LIGHT SCATTERING; MAXIMUM TOLERATED DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SOLID TUMOR; SURFACE PLASMON RESONANCE; ZETA POTENTIAL;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICELLES; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS; POLYMERS; SOLUBILITY;

EID: 84862728843     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2012.689284     Document Type: Review

References (116)

1. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5(3):161-71 (Pubitemid 40314948)
2. Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des 2010;16(16):1882-92
3. Seigneuric R, Markey L, Nuyten DS, et al. From nanotechnology to nanomedicine: applications to cancer research. Curr Mol Med 2010;10(7):640-52
4. Venugopal J, Prabhakaran MP, Low S, et al. Nanotechnology for nanomedicine and delivery of drugs. Curr Pharm Des 2008;14(22):2184-200
5. Vicent MJ, Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol 2006;24(1):39-47 (Pubitemid 43017749)
6. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006;45(8):1198-215 A review on the current status of polymer therapeutics. (Pubitemid 44097641)
7. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975;51:135-53 Landmark publication introducing the concept of polymeric prodrug.
8. Wieder KJ, Palczuk NC, van Es T, Davis FF. Some properties of polyethylene glycol: phenylalanine ammonia-lyase adducts. J Biol Chem 1979;254(24):12579-87
9. Davis FF. The origin of pegnology. Adv Drug Deliv Rev 2002;54(4):457-8 Commentary on protein PEGylation. (Pubitemid 34615542)
10. Vasey PA, Kaye SB, Morrison R, et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl) methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res 1999;5(1):83-94 (Pubitemid 29045181)
11. Yokoyama M, Miyauchi M, Yamada N, et al. Polymer micelles as novel drug carrier: adriamycin-conjugated poly (ethylene glycol)-poly(aspartic acid) block copolymer. J Control Release 1990;11(1-3):269-78 (Pubitemid 20070104)
12. Putnam D, Kopecek J. Polymer conjugates with anticancer activity. Adv Polym Sci 1995;122:55-123
13. Duncan R, Kopecek J. Soluble synthetic polymers as potential drug carriers. Adv Polym Sci 1984;57:51-101
14. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 1992;3(3):175-210
15. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2(5):347-60 (Pubitemid 37361705)
16. Thanou M, Duncan R. Polymer--protein and polymer--drug conjugates in cancer therapy. Curr Opin Investig Drugs 2003;4(6):701-9 (Pubitemid 36916711)
17. Vicent MJ, Dieudonne L, Carbajo RJ, Pineda-Lucena A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin Drug Deliv 2008;5(5):593-614 (Pubitemid 351888105)
18. Greco F, Vicent MJ. Polymer--drug conjugates: current status and future trends. Front Biosci 2008;13:2744-56 (Pubitemid 351611606)
19. Ulbrich K, Konak C, Tuzar Z, Kopecek J. Solution properties of drug carriers based on poly[N-(2-hydroxypropyl)methacrylamide] containing biodegradable bonds. Makromol Chem 1987;188(6):1261-72 First polymer assembly drug carrier based on HPMA-drug conjugates.
20. Oerlemans C, Bult W, Bos M, et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res 2010;27(12):2569-89
21. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005;10(21):1451-8 (Pubitemid 41483874)
22. Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009;61(13):1177-88 Review describing PEG conjugates of proteins or low molecular weight drugs in clinical development.
23. Lee GY, Park K, Kim SY, Byun Y. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm 2007;67(3):646-54 (Pubitemid 47576605)
24. Melancon MP, Li C. Multifunctional synthetic poly(L-glutamic acid)-based cancer therapeutic and imaging agents. Mol imaging 2011;10(1):28-42
25. Singer JW, Bhatt R, Tulinsky J, et al. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74(1-3):243-7 (Pubitemid 32727627)
26. Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clin Lung Cancer 2004;6(Suppl 2):S85-8
27. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2007;7(4):415-22 (Pubitemid 46681797)
28. Albain KS, Belani CP, Bonomi P, et al. Pioneer: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 2006;7(6):417-19 (Pubitemid 44043553)
29. Homsi J, Simon GR, Garrett CR, et al. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res 2007;13(19):5855-61 (Pubitemid 47583911)
30. Li C, Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv Drug Deliv Rev 2008;60(8):886-98
31. Lee YK. Preparation and characterization of folic acid linked poly(L-glutamate) nanoparticles for cancer targeting. Macromol Res 2006;14(3):387-93
32. Feng ZL, Zhao G, Yu L, et al. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane. Cancer Chemother Pharmacol 2010;65(5):923-30
33. Wang XH, Zhao G, Van S, et al. Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts. Cancer Chemother Pharmacol 2010;65(3):515-26
34. Yang DB, Van S, Liu J, et al. Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment. Int J Nanomed 2011;6:2557-66
35. Van S, Das SK, Wang XH, et al. Synthesis, characterization, and biological evaluation of poly(Lgamma-glutamyl-glutamine)-paclitaxel nanoconjugate. Int J Nanomed 2010;5:825-37
36. Brown MB, Jones SA. Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 2005;19(3):308-18 (Pubitemid 40691707)
37. Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010;141(1):2-12
38. Misra S, Heldin P, Hascall VC, et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011;278(9):1429-43
39. Yang B, Zhang L, Turley EA. Identification of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J Biol Chem 1993;268(12):8617-23 (Pubitemid 23118644)
40. Kouvidi K, Berdiaki A, Nikitovic D, et al. Role of receptor for hyaluronic acid-mediated motility (RHAMM) in low molecular weight hyaluronan (LMWHA)-mediated fibrosarcoma cell adhesion. J Biol Chem 2011;286(44):38509-20
41. Murano E, Perin D, Khan R, Bergamin M. Hyaluronan: from biomimetic to industrial business strategy. Nat Prod Commun 2011;6(4):555-72
42. Ossipov DA. Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv 2010;7(6):681-703
43. Lee H, Lee K, Park TG. Hyaluronic acid-paclitaxel conjugate micelles: synthesis, characterization, and antitumor activity. Bioconjug Chem 2008;19(6):1319-25 (Pubitemid 351874956)
44. Sasisekharan R, Venkataraman G. Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 2000;4(6):626-31
45. Rabenstein DL. Heparin and heparan sulfate: structure and function. Nat Prod Rep 2002;19(3):312-31 (Pubitemid 34656777)
46. Damus PS, Hicks M, Rosenberg RD. Anticoagulant action of heparin. Nature 1973;246(5432):355-7
47. Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res 2010;125(Suppl 2):S66-71
48. Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci 2010;93:335-49
49. Skidmore MA, Guimond SE, Rudd TR, et al. The activities of heparan sulfate and its analogue heparin are dictated by biosynthesis, sequence, and conformation. Connect Tissue Res 2008;49(3):140-4
50. Wang Y, Xin DC, Liu KJ, et al. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. Bioconjug Chem 2009;20(12):2214-21
51. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012;157(2):168-82
52. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132(3):171-83
53. Miele E, Spinelli GP, Miele E, et al. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 2009;4:99-105 Review discribing the clinical studies of Abraxane® in the treatment of breast cancer.
54. Esmaeili F, Dinarvand R, Ghahremani MH, et al. Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 2009;98(8):2718-30
55. Tokiwa Y, Calabia BP. Biodegradability and biodegradation of poly(lactide). Appl Microbiol Biotechnol 2006;72(2):244-51 (Pubitemid 44273047)
56. Tokiwa Y, Jarerat A. Biodegradation of poly(L-lactide). Biotechnol Lett 2004;26(10):771-7 (Pubitemid 38982853)
57. Inkinen S, Hakkarainen M, Albertsson AC, Sodergard A. From lactic acid to poly(lactic acid) (PLA): characterization and analysis of PLA and its precursors. Biomacromolecules 2011;12(3):523-32
58. Zhang X, Li Y, Chen X, et al. Synthesis and characterization of the paclitaxel/ MPEG-PLA block copolymer conjugate. Biomaterials 2005;26(14):2121-8 (Pubitemid 39575355)
59. Xu X, Zhang X, Wang X, et al. Comparative study of paclitaxel physically encapsulated in and chemically conjugated with PEG-PLA. Polym Adv Technol 2009;20(11):843-8
60. Wang Z, Hu X, Yue J, Jing XB. Experimental study on biodegradable polymer-paclitaxel conjugate micelles for chemotherapy of C6 glioma. J Control Release 2011;152(Suppl 1):e41-2
61. Yoo HS, Park TG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA-PEG block copolymer. J Control Release 2001;70(1-2):63-70 (Pubitemid 32144793)
62. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release 2004;96(2):273-83 (Pubitemid 38481509)
63. Jin C, Qian NS, Zhao W, et al. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab′)(2) for hepatocellular carcinoma. Biomacromolecules 2010;11(9):2422-31
64. Jin C, Yang WQ, Bai L, et al. Preparation and characterization of targeted DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab′)2 for treatment of hepatocellular carcinoma. J Control Release 2011;152(Suppl 1):e14-15
65. Mikhail AS, Allen C. Poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromolecules 2010;11(5):1273-80
66. Varnell DF, Moskala EJ, Painter PC, Coleman MM. On the application of fourier transform infrared spectroscopy to the elucidation of specific interactions in miscible polyester-poly(vinyl chloride) blends. Polym Eng Sci 1983;23(12):658-62
67. Surewicz WK, Mantsch HH, Chapman D. Determination of protein secondary structure by fourier transform infrared spectroscopy: a critical assessment. Biochemistry 1993;32(2):389-94 (Pubitemid 23034873)
68. Kumirska J, Czerwicka M, Kaczynski Z, et al. Application of spectroscopic methods for structural analysis of chitin and chitosan. Mar drugs 2010;8(5):1567-636
69. Zhang WL, Huang J, Fan NQ, et al. Nanomicelle with long-term circulation and enhanced stability of camptothecin based on mPEGylated alpha,-poly (L-aspartic acid)-camptothecin conjugate. Colloids Surf B Biointerfaces 2010;81(1):297-303
70. Li GL, Liu JY, Pang Y, et al. Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery. Biomacromolecules 2011;12(6):2016-26
71. Astafieva I, Zhong XF, Eisenberg A. Critical micellization phenomena in block polyelectrolyte solutions. Macromolecules 1993;26(26):7339-52
72. Miyagishi S, Okada K, Asakawa T. Salt effect on critical micelle concentrations of nonionic surfactants, N-Acyl-N-methylglucamides (MEGA-n). J Colloid Interface Sci 2001;238(1):91-5 (Pubitemid 32896795)
73. Al-Soufi W, Pineiro L, Novo M. A model for monomer and micellar concentrations in surfactant solutions: application to conductivity, NMR, diffusion, and surface tension data. J Colloid Interface Sci 2012;370(1):102-10
74. Alam MS, Ghosh G, Mandal AB, Kabir ud D. Aggregation behavior and interaction of an amphiphilic drug imipramine hydrochloride with cationic surfactant cetyltrimethylammonium bromide: light scattering studies. Colloids Surf B Biointerfaces 2011;88(2):779-84
75. Zhao CL, Winnik MA, Riess G, Croucher MD. Fluorescence probe techniques used to study micelle formation in water-soluble block copolymers. Langmuir 1990;6(2):514-16 (Pubitemid 20663816)
76. Venkataraman S, Hedrick JL, Ong ZY, et al. The effects of polymeric nanostructure shape on drug delivery. Adv Drug Deliv Rev 2011;63(14-15):1228-46
77. Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010;6(6):714-29 Exhaustive review describing the progress regarding the targeting mechanisms of anticancer drugs to the tumor site using polymeric micelles.
78. Wu LB, Zhang J, Watanabe W. Physical and chemical stability of drug nanoparticles. Adv Drug Deliv Rev 2011;63(6):456-69 Review describing the stability of drug nanoparticles dispersed in the liquid medium.
79. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387-92 One of the initial reviews introducing the EPR effect as a passive targeting strategy for macromolecular drugs. (Pubitemid 17221789)
80. Kwon G, Suwa S, Yokoyama M, et al. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J Control Release 1994;29(1-2):17-23
81. Lyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11(17-18):812- 18 (Pubitemid 44280021)
82. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63(3):136-51
83. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011;63(3):131-5
84. Hu XL, Jing XB. Biodegradable amphiphilic polymer-drug conjugate micelles. Expert Opin Drug Deliv 2009;6(10):1079-90 Excellent review describing the biodegradable amphiphilic polymer--drug conjugate micelles.
85. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv 2009;6(3):285-304
86. Park JH, Lee S, Kim JH, et al. Polymeric nanomedicine for cancer therapy. Prog Polym Sci 2008;33(1):113-37 (Pubitemid 350278530)
87. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008;60(15):1615-26
88. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 2005;94(10):2135-46 (Pubitemid 41665275)
89. Scomparin A, Salmaso S, Bersani S, et al. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery. Eur J Pharm Sci 2011;42(5):547-58
90. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release 2002;82(1):17-27 (Pubitemid 34775044)
91. Vicent MJ, Ringsdorf H, Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv Drug Deliv Rev 2009;61(13):1117-20
92. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011;22(4):492-501
93. Tong R, Cheng JJ. Anticancer polymeric nanomedicines. Polym Rev 2007;47(3):345-81 (Pubitemid 47240845)
94. Sanchis J, Canal F, Lucas R, Vicent MJ. Polymer--drug conjugates for novel molecular targets. Nanomedicine 2010;5(6):915-35
95. Yang DB, Van S, Jiang XG, Yu L. Novel free paclitaxel-loaded poly(L-gamma-glutamylglutamine)-paclitaxel nanoparticles. Int J Nanomed 2011;6:85-91
96. Yang DB, Van S, Shu YY, et al. Synthesis, characterization, and in vivo efficacy evaluation of PGG-docetaxel conjugate for potential cancer chemotherapy. Int J Nanomed 2012;7:581-9
97. Galer CE, Sano D, Ghosh SC, et al. Hyaluronic acid-paclitaxel conjugate inhibits growth of human squamous cell carcinomas of the head and neck via a hyaluronic acid-mediated mechanism. Oral Oncol 2011;47(11):1039-47
98. Xin DC, Wang Y, Xiang JN. The use of amino acid linkers in the conjugation of paclitaxel with hyaluronic acid as drug delivery system: synthesis, self-assembled property, drug release, and in vitro efficiency. Pharm Res 2010;27(2):380-9
99. Manju S, Sreenivasan K. Conjugation of curcumin onto hyaluronic acid enhances its aqueous solubility and stability. J Colloid Interface Sci 2011;359(1):318-25
100. Wang Y, Xin DC, Liu KJ, Xiang JN. Heparin-paclitaxel conjugates using mixed anhydride as intermediate: synthesis, influence of polymer structure on drug release, anticoagulant activity and in vitro efficiency. Pharm Res 2009;26(4):785-93
101. Fitzpatrick JJ, Garnett MC. Studies on the mechanism of action of an MTX-HSA-MoAb conjugate. Anticancer Drug Des 1995;10(1):11-24
102. Schmid B, Chung DE, Warnecke A, et al. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy. Bioconjug Chem 2007;18(3):702-16 (Pubitemid 47010789)
103. Qu XL, Yang C, Zhang J, et al. In vitro evaluation of a Folate-bovine serum albumin-doxorubicin conjugate. J Drug Target 2010;18(5):351-61
104. Xu R, Fisher M, Juliano RL. Targeted albumin-based nanoparticles for delivery of amphipathic drugs. Bioconjug Chem 2011;22(5):870-8
105. Xie ZG, Lu TC, Chen XS, et al. Synthesis, self-assembly in water, and cytotoxicity of MPEG-block-PLLA/DX conjugates. J Biomed Mater Res A 2009;88(1):238-45
106. Xie ZG, Hu XL, Chen XS, et al. A biodegradable diblock copolymer poly (ethylene glycol)-block-poly(L-lactide-co-2-methyl-2-carboxyl-propylene carbonate): docetaxel and RGD conjugation. J Appl Polym Sci 2008;110:2961-70
107. Hu XL, Liu S, Huang YB, et al. Biodegradable block copolymer-doxorubicin conjugates via different linkages: preparation, characterization, and in vitro evaluation. Biomacromolecules 2010;11(8):2094-102
108. Xie ZG, Lu TC, Chen XS, et al. Triblock poly(lactic acid)-b-poly(ethylene glycol)-b-poly(lactic acid)/paclitaxel conjugates: synthesis, micellization, and cytotoxicity. J Appl Polym Sci 2007;105:2271-9
109. Nakanishi T, Fukushima S, Okamoto K, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001;74(1-3):295-302 (Pubitemid 32727635)
110. Bae Y, Jang WD, Nishiyama N, et al. Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery. Mol Biosyst 2005;1(3):242-50 (Pubitemid 41442434)
111. Bae Y, Nishiyama N, Kataoka K. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug Chem 2007;18(4):1131-9 (Pubitemid 47122634)
112. Bae Y, Kataoka K. Significant enhancement of antitumor activity and bioavailability of intracellular pH-sensitive polymeric micelles by folate conjugation. J Control Release 2006;116(2):e49-50
113. Fan NQ, Duan KR, Wang CY, et al. Fabrication of nanomicelle with enhanced solubility and stability of camptothecin based on alpha,-poly [(N-carboxybutyl)-L-aspartamide]-camptothecin conjugate. Colloids Surf B Biointerfaces 2010;75(2):543-9
114. Hruby M, Konak C, Ulbrich K. Polymeric micellar pH-sensitive drug delivery system for doxorubicin. J Control Release 2005;103(1):137-48 (Pubitemid 40248568)
115. Lee Y, Park SY, Mok H, Park TG. Synthesis, characterization, antitumor activity of pluronic mimicking copolymer micelles conjugated with doxorubicin via acid-cleavable linkage. Bioconjug Chem 2008;19(2):525-31 (Pubitemid 351294925)
116. Zhao YZ, Sun CZ, Lu CT, et al. Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOX-P) in vitro. Cancer Lett 2011;311(2):187-94